Aurinia Pharmaceuticals Announces Results From A Phase 1 Single-ascending-dose Study Of Aritinercept (AUR200) Doses Of 5 mg, 25 mg, 75 mg, 150 mg, 225 mg And 300 mg And Placebo, Administered By Subcutaneous Injection, In 61 Healthy Subjects

Author: Benzinga Newsdesk | June 30, 2025 05:12am

Aritinercept was well tolerated at all dose levels tested. There were no treatment-related Grade ≥3 adverse events, there were no treatment‑related serious adverse events (SAEs) and there were no discontinuations due to treatment-related adverse events. Adverse events that occurred in more than one subject included injection site reactions (24% aritinercept, 13% placebo), headache (11% aritinercept, 7% placebo), upper respiratory tract infection (7% aritinercept, 0% placebo) and back pain (4% aritinercept, 0% placebo). All injection site reactions were Grade 1.

Single doses of aritinercept led to robust and long-lasting reductions in immunoglobulins (antibodies). Specifically, mean reductions from baseline to Day 28 of up to 48%, 55% and 20% were observed for immunoglobulin A (IgA), immunoglobulin M (IgM) and immunoglobulin G (IgG), respectively.

Posted In: AUPH